L3VLUP
ProSign in

COO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

COOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • COO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCOOVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 2022none listed holders, n.a.22 holders, $18.4bn
Q4 2022none listed holders, n.a.28 holders, $18.4bn
Q1 2023none listed holders, n.a.26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 202421 holders, $3.0bn31 holders, $29.8bn
Q2 202419 holders, $2.5bn29 holders, $33.4bn
Q3 202419 holders, $3.3bn27 holders, $33.5bn
Q4 202416 holders, $2.9bn26 holders, $28.5bn
Q1 202519 holders, $3.2bn21 holders, $35.4bn
Q2 202521 holders, $3.0bn21 holders, $32.3bn
Q3 202516 holders, $3.2bn22 holders, $25.9bn
Q4 202517 holders, $3.4bn26 holders, $31.8bn
Q1 202613 holders, $2.6bn25 holders, $31.8bn
Q2 202619 holders, $2.6bn26 holders, $34.6bn
COO

Cooper Cos Inc

Holders
19
Reported value
$2.5bn
Buyers
10
Sellers
9

Breadth +1 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only COO (9)

Citadel Advisors LLC, ExodusPoint Capital Management LP, GAMCO Investors Inc, Holocene Advisors LP, Point72 Asset Management LP, Quantbot Technologies LP, Tudor Investment Corp, Winton Group Ltd, Woodline Partners LP

Only VRTX (19)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Jane Street Group LLC, Man Group PLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →